✦ LIBER ✦

Optimal adjuvant hormonal therapy in postmenopausal women with hormone-receptor-positive early breast cancer: have we answered the question?

✍ Scribed by Alfonso Sánchez-Muñz; Nuria Ribelles; Emilio Alba

Publisher: Springer Milan
Year: 2010
Tongue: Spanish
Weight: 561 KB
Volume: 12
Category: Article
ISSN: 1699-048X
DOI: 10.1007/s12094-010-0566-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Racial/ethnic differences in initiation

Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer

✍ Jennifer C. Livaudais; Dawn L. Hershman; Laurel Habel; Lawrence Kushi; Scarlett 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 201 KB

Optimizing aromatase inhibitor integrati

Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer

✍ Rowan T. Chlebowski 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 274 KB

Cost-effectiveness of letrozole versus t

Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective

✍ Thomas E. Delea; Khalid El-Ouagari; Jonathan Karnon; Oleg Sofrygin 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 301 KB

Optimal treatment strategies in postmeno

Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer

✍ Joseph Gligorov; Jean-Pierre Lotz 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 323 KB

Prognostic factors of early distant recu

Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy : Results of a retrospective analysis

✍ Marc Debled; Gaëtan MacGrogan; Véronique Brouste; Simone Mathoulin-Pelissier; Mi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 1 views

## Abstract ## BACKGROUND Current adjuvant hormone therapy in postmenopausal women with breast cancer is debatable between upfront aromatase inhibitors (AIs) and sequential treatment with tamoxifen. A major concern is the higher rate of early recurrences observed with sequential treatment. The aut

Optimizing the use of aromatase inhibito

Optimizing the use of aromatase inhibitors in adjuvant therapy for postmenopausal patients with hormone-responsive early breast cancer: current and future prospects

✍ Walter Jonat; Felix Hilpert 📂 Article 📅 2006 🏛 Springer-Verlag 🌐 English ⚖ 412 KB